The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Jérémy Magalon - One of the best experts on this subject based on the ideXlab platform.
-
response to adipose Stromal Vascular Fraction and regenerative therapy in ssc response to the article by magalon et al by de benedetto et al
Annals of the Rheumatic Diseases, 2020Co-Authors: Jérémy Magalon, Francoise Dignatgeorge, Melanie Velier, Stephanie Simoncini, B Granel, Pascale Paul, Florence SabatierAbstract:We would like to thank Di Benedetto et al 1 for their constructive comments on our recent publication in Annals of Rheumatic Disease entitled ‘Molecular profile and proangiogenic activity of the adipose-derived Stromal Vascular Fraction used as an autologous innovative medicinal product in patients with systemic sclerosis’.2 Di Benedetto et al mentioned that the profibrotic signature of mesenchymal stem cells (MSCs) derived from patients with the diffuse cutaneous form of systemic sclerosis (dc-SSc) has been established from previous works. In line with this, they discussed the potential risk of increasing the fibrotic burden by using autologous adipose-derived Stromal Vascular Fraction (ADVSF) in which MSCs are highly represented. Although this is a fair question in the context of developing MSCs-based therapy for SSc, we would like to emphasise the fact that the biological findings …
-
Autologous adipose-derived Stromal Vascular Fraction and scarred vocal folds: first clinical case report
Stem Cell Research and Therapy, 2018Co-Authors: Alexia Mattei, Jérémy Magalon, J. Veran, Florence Sabatier, Melanie Velier, Baptiste Bertrand, Fanny Grimaud, Joana Révis, Patrick Dessi, Antoine GiovanniAbstract:Patients with scarred vocal folds (congenitally or following phonosurgery) are currently difficult to treat and present a dysphonia, often disabling in daily life. Several therapies are available on the market but the results of these are often disappointing. The autologous adipose-derived Stromal Vascular Fraction (ADSVF) is recognized as an easily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties. We present here the case of a 43-year-old woman who had a severe dysphonia associated with scarred vocal folds after a phonosurgery and was resistant to conventional medical and surgical treatments. She received a local administration of autologous ADSVF. The protocol involved, on the same day, adipose tissue extraction, ADSVF preparation, and then local injection (0.45ml of ADSVF in each vocal fold, for a total of 12.2 million ADSVF viable cells). No serious adverse events have been described. One year following the surgery, the laryngoscopic aspect and the majority of voice parameters had improved, in particular the Voice Handicap Index decreasing from 75 to 9. The perceptual analysis found the voice to be less hoarse and more stable, without breathiness. The case of this patient highlights the therapeutic potential of ADSVF for such applications (trial registration, ClinicalTrials.gov NCT02622464; registered 4 December 2015).
-
Long-term follow-up after autologous adipose-derived Stromal Vascular Fraction injection into fingers in systemic sclerosis patients
Current Research in Translational Medicine, 2017Co-Authors: Aurélie Daumas, Jérémy Magalon, E. Jouve, R. Truillet, D. Casanova, J. Veran, Audrey Benyamine, Françoise Dignat-george, Luca Giraudo, G. MagalonAbstract:Introduction: Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived Stromal Vascular Fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I open-label clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived Stromal Vascular Fraction. Six and 12-month data have been reported. As patients were followed in our medical centre, we report their longer-term outcome beyond the end of the trial. Patients and method: Twelve females, mean age 54.5 ± 10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30 months after treatment. Results: Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted. Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion. Conclusion: Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived Stromal Vascular Fraction injection. Two randomized double blind, placebo-controlled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients.
-
histological and urodynamic effects of autologous Stromal Vascular Fraction extracted from fat tissue with minimal ex vivo manipulation in a porcine model of intrinsic sphincter deficiency
The Journal of Urology, 2016Co-Authors: R Boissier, Jérémy Magalon, J. Veran, Florence Sabatier, Laurent Giraudo, Sophie Giusiano, Stephane Garcia, Francoise Dignatgeorge, Laurent ArnaudAbstract:Purpose: To evaluate the healing abilities of autologous stem cell therapy (Stromal Vascular Fraction) prepared from adipose tissue we used an automated system without an ex vivo culture phase in a pig model of intrinsic sphincteric deficiency.Materials and Methods: A total of 15 pigs underwent endoscopic section of the urethral sphincter. Animals were then randomly assigned to 3 groups, including 1) controls without Stromal Vascular Fraction injection, 2) early injection with Stromal Vascular Fraction 2 to 3 days after section and 3) late Stromal Vascular Fraction injection delivery 30 days after injury. Extraction and Stromal Vascular Fraction injection were performed as a single procedure. The Stromal Vascular Fraction was characterized by flow cytometry. Mesenchymal stem cell-like cells were enumerated by clonogenicity (cfu fibroblast) assay. Study end points included histological assessment of the urethral injury surface and urodynamics to determine maximum urethral pressure.Results: Flow cytometry a...
-
Autologous adipose-derived Stromal Vascular Fraction in patients with systemic sclerosis: 12-month follow-up
Rheumatology, 2016Co-Authors: Perrine Guillaume-jugnot, Aurélie Daumas, Jérémy Magalon, R. Truillet, D. Casanova, Laurent Giraudo, Elisabeth Jouve, Pierre Sebastien Nguyen, Stephanie Mallet, J. VeranAbstract:Objective. Impaired hand function greatly contributes to disability and reduced quality of life in SSc patients. Autologous adipose-derived Stromal Vascular Fraction (ADSVF) is recognized as an easily accessible source of regenerative cells. We reported positive 6-month safety and efficacy results from an open-label clinical trial assessing s.c. injection of autologous ADSVF into the fingers in SSc patients. The objective of this report is to describe the effects at 12 months. Methods. Twelve females, mean age 54.5 years (S.D. 10.3), were assessed 1 year after ADSVF injection. Patients were eligible if they had a Cochin Hand Function Scale score >20/90. ADSVF was obtained from lipoaspirate using an automated processing system and subsequently injected into the s.c. tissue of each finger in contact with neuroVascular pedicles in a one-time procedure. Endpoints were changes in hand disability and skin fibrosis, Vascular manifestations, pain and quality of life at the 12 month follow-up. During the visit, patients estimated the benefit of the procedure with a specific self-completed questionnaire. Results. A significant decrease from baseline of 51.3% (P< 0.001) for Cochin Hand Function Scale score, 63.2% (P< 0.001) for RP severity and 46.8% (P = 0.001) for quality of life (Scleroderma Health Assessment Questionnaire) was observed. A significant improvement of finger oedema, skin sclerosis, motion and strength of the hands and of the Vascular suppression score was also noted. The reduction in hand pain approached statistical significance (P = 0.052). The questionnaire revealed a benefit in daily activities, housework and social activities. Conclusion. ADSVF injection is a promising therapy and appears to have benefits that extend for at least 1 year.
Florence Sabatier - One of the best experts on this subject based on the ideXlab platform.
-
response to adipose Stromal Vascular Fraction and regenerative therapy in ssc response to the article by magalon et al by de benedetto et al
Annals of the Rheumatic Diseases, 2020Co-Authors: Jérémy Magalon, Francoise Dignatgeorge, Melanie Velier, Stephanie Simoncini, B Granel, Pascale Paul, Florence SabatierAbstract:We would like to thank Di Benedetto et al 1 for their constructive comments on our recent publication in Annals of Rheumatic Disease entitled ‘Molecular profile and proangiogenic activity of the adipose-derived Stromal Vascular Fraction used as an autologous innovative medicinal product in patients with systemic sclerosis’.2 Di Benedetto et al mentioned that the profibrotic signature of mesenchymal stem cells (MSCs) derived from patients with the diffuse cutaneous form of systemic sclerosis (dc-SSc) has been established from previous works. In line with this, they discussed the potential risk of increasing the fibrotic burden by using autologous adipose-derived Stromal Vascular Fraction (ADVSF) in which MSCs are highly represented. Although this is a fair question in the context of developing MSCs-based therapy for SSc, we would like to emphasise the fact that the biological findings …
-
Autologous adipose-derived Stromal Vascular Fraction and scarred vocal folds: first clinical case report
Stem Cell Research and Therapy, 2018Co-Authors: Alexia Mattei, Jérémy Magalon, J. Veran, Florence Sabatier, Melanie Velier, Baptiste Bertrand, Fanny Grimaud, Joana Révis, Patrick Dessi, Antoine GiovanniAbstract:Patients with scarred vocal folds (congenitally or following phonosurgery) are currently difficult to treat and present a dysphonia, often disabling in daily life. Several therapies are available on the market but the results of these are often disappointing. The autologous adipose-derived Stromal Vascular Fraction (ADSVF) is recognized as an easily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties. We present here the case of a 43-year-old woman who had a severe dysphonia associated with scarred vocal folds after a phonosurgery and was resistant to conventional medical and surgical treatments. She received a local administration of autologous ADSVF. The protocol involved, on the same day, adipose tissue extraction, ADSVF preparation, and then local injection (0.45ml of ADSVF in each vocal fold, for a total of 12.2 million ADSVF viable cells). No serious adverse events have been described. One year following the surgery, the laryngoscopic aspect and the majority of voice parameters had improved, in particular the Voice Handicap Index decreasing from 75 to 9. The perceptual analysis found the voice to be less hoarse and more stable, without breathiness. The case of this patient highlights the therapeutic potential of ADSVF for such applications (trial registration, ClinicalTrials.gov NCT02622464; registered 4 December 2015).
-
histological and urodynamic effects of autologous Stromal Vascular Fraction extracted from fat tissue with minimal ex vivo manipulation in a porcine model of intrinsic sphincter deficiency
The Journal of Urology, 2016Co-Authors: R Boissier, Jérémy Magalon, J. Veran, Florence Sabatier, Laurent Giraudo, Sophie Giusiano, Stephane Garcia, Francoise Dignatgeorge, Laurent ArnaudAbstract:Purpose: To evaluate the healing abilities of autologous stem cell therapy (Stromal Vascular Fraction) prepared from adipose tissue we used an automated system without an ex vivo culture phase in a pig model of intrinsic sphincteric deficiency.Materials and Methods: A total of 15 pigs underwent endoscopic section of the urethral sphincter. Animals were then randomly assigned to 3 groups, including 1) controls without Stromal Vascular Fraction injection, 2) early injection with Stromal Vascular Fraction 2 to 3 days after section and 3) late Stromal Vascular Fraction injection delivery 30 days after injury. Extraction and Stromal Vascular Fraction injection were performed as a single procedure. The Stromal Vascular Fraction was characterized by flow cytometry. Mesenchymal stem cell-like cells were enumerated by clonogenicity (cfu fibroblast) assay. Study end points included histological assessment of the urethral injury surface and urodynamics to determine maximum urethral pressure.Results: Flow cytometry a...
-
State of the art. Autologous fat graft and adipose tissue-derived Stromal Vascular Fraction injection for hand therapy in systemic sclerosis patients
Current Research in Translational Medicine, 2016Co-Authors: Perrine Guillaume-jugnot, Aurélie Daumas, Jérémy Magalon, J. Veran, Florence Sabatier, Guy Magalon, Nolwenn Sautereau, B GranelAbstract:Systemic sclerosis is an autoimmune disease characterized by sclerosis (hardening) of the skin and deep viscera associated with microVascular functional and structural alteration, which leads to chronic ischemia. In the hands of patients, ischemic and fibrotic damages lead to both pain and functional impairment. Hand disability creates a large burden in professional and daily activities, with social and psychological consequences. Currently, the proposed therapeutic options for hands rely mainly on hygienic measures, vasodilatator drugs and physiotherapy, but have many constraints and limited effects. Developing an innovative therapeutic approach is crucial to reduce symptoms and improve the quality of life. The discovery of adult stem cells from adipose tissue has increased the interest to use adipose tissue in plastic and regenerative surgery. Prepared as freshly isolated cells for immediate autologous transplantation, adipose tissue-derived stem cell therapy has emerged as a therapeutic alternative for the regeneration and repair of damaged tissues. We aim to update literature in the interest of autologous fat graft or adipose derived from Stromal Vascular Fraction cell-based therapy for the hands of patients who suffer from systemic sclerosis.
J. Veran - One of the best experts on this subject based on the ideXlab platform.
-
Autologous adipose-derived Stromal Vascular Fraction and scarred vocal folds: first clinical case report
Stem Cell Research and Therapy, 2018Co-Authors: Alexia Mattei, Jérémy Magalon, J. Veran, Florence Sabatier, Melanie Velier, Baptiste Bertrand, Fanny Grimaud, Joana Révis, Patrick Dessi, Antoine GiovanniAbstract:Patients with scarred vocal folds (congenitally or following phonosurgery) are currently difficult to treat and present a dysphonia, often disabling in daily life. Several therapies are available on the market but the results of these are often disappointing. The autologous adipose-derived Stromal Vascular Fraction (ADSVF) is recognized as an easily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties. We present here the case of a 43-year-old woman who had a severe dysphonia associated with scarred vocal folds after a phonosurgery and was resistant to conventional medical and surgical treatments. She received a local administration of autologous ADSVF. The protocol involved, on the same day, adipose tissue extraction, ADSVF preparation, and then local injection (0.45ml of ADSVF in each vocal fold, for a total of 12.2 million ADSVF viable cells). No serious adverse events have been described. One year following the surgery, the laryngoscopic aspect and the majority of voice parameters had improved, in particular the Voice Handicap Index decreasing from 75 to 9. The perceptual analysis found the voice to be less hoarse and more stable, without breathiness. The case of this patient highlights the therapeutic potential of ADSVF for such applications (trial registration, ClinicalTrials.gov NCT02622464; registered 4 December 2015).
-
Long-term follow-up after autologous adipose-derived Stromal Vascular Fraction injection into fingers in systemic sclerosis patients
Current Research in Translational Medicine, 2017Co-Authors: Aurélie Daumas, Jérémy Magalon, E. Jouve, R. Truillet, D. Casanova, J. Veran, Audrey Benyamine, Françoise Dignat-george, Luca Giraudo, G. MagalonAbstract:Introduction: Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived Stromal Vascular Fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I open-label clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived Stromal Vascular Fraction. Six and 12-month data have been reported. As patients were followed in our medical centre, we report their longer-term outcome beyond the end of the trial. Patients and method: Twelve females, mean age 54.5 ± 10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30 months after treatment. Results: Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted. Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion. Conclusion: Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived Stromal Vascular Fraction injection. Two randomized double blind, placebo-controlled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients.
-
histological and urodynamic effects of autologous Stromal Vascular Fraction extracted from fat tissue with minimal ex vivo manipulation in a porcine model of intrinsic sphincter deficiency
The Journal of Urology, 2016Co-Authors: R Boissier, Jérémy Magalon, J. Veran, Florence Sabatier, Laurent Giraudo, Sophie Giusiano, Stephane Garcia, Francoise Dignatgeorge, Laurent ArnaudAbstract:Purpose: To evaluate the healing abilities of autologous stem cell therapy (Stromal Vascular Fraction) prepared from adipose tissue we used an automated system without an ex vivo culture phase in a pig model of intrinsic sphincteric deficiency.Materials and Methods: A total of 15 pigs underwent endoscopic section of the urethral sphincter. Animals were then randomly assigned to 3 groups, including 1) controls without Stromal Vascular Fraction injection, 2) early injection with Stromal Vascular Fraction 2 to 3 days after section and 3) late Stromal Vascular Fraction injection delivery 30 days after injury. Extraction and Stromal Vascular Fraction injection were performed as a single procedure. The Stromal Vascular Fraction was characterized by flow cytometry. Mesenchymal stem cell-like cells were enumerated by clonogenicity (cfu fibroblast) assay. Study end points included histological assessment of the urethral injury surface and urodynamics to determine maximum urethral pressure.Results: Flow cytometry a...
-
Autologous adipose-derived Stromal Vascular Fraction in patients with systemic sclerosis: 12-month follow-up
Rheumatology, 2016Co-Authors: Perrine Guillaume-jugnot, Aurélie Daumas, Jérémy Magalon, R. Truillet, D. Casanova, Laurent Giraudo, Elisabeth Jouve, Pierre Sebastien Nguyen, Stephanie Mallet, J. VeranAbstract:Objective. Impaired hand function greatly contributes to disability and reduced quality of life in SSc patients. Autologous adipose-derived Stromal Vascular Fraction (ADSVF) is recognized as an easily accessible source of regenerative cells. We reported positive 6-month safety and efficacy results from an open-label clinical trial assessing s.c. injection of autologous ADSVF into the fingers in SSc patients. The objective of this report is to describe the effects at 12 months. Methods. Twelve females, mean age 54.5 years (S.D. 10.3), were assessed 1 year after ADSVF injection. Patients were eligible if they had a Cochin Hand Function Scale score >20/90. ADSVF was obtained from lipoaspirate using an automated processing system and subsequently injected into the s.c. tissue of each finger in contact with neuroVascular pedicles in a one-time procedure. Endpoints were changes in hand disability and skin fibrosis, Vascular manifestations, pain and quality of life at the 12 month follow-up. During the visit, patients estimated the benefit of the procedure with a specific self-completed questionnaire. Results. A significant decrease from baseline of 51.3% (P< 0.001) for Cochin Hand Function Scale score, 63.2% (P< 0.001) for RP severity and 46.8% (P = 0.001) for quality of life (Scleroderma Health Assessment Questionnaire) was observed. A significant improvement of finger oedema, skin sclerosis, motion and strength of the hands and of the Vascular suppression score was also noted. The reduction in hand pain approached statistical significance (P = 0.052). The questionnaire revealed a benefit in daily activities, housework and social activities. Conclusion. ADSVF injection is a promising therapy and appears to have benefits that extend for at least 1 year.
-
State of the art. Autologous fat graft and adipose tissue-derived Stromal Vascular Fraction injection for hand therapy in systemic sclerosis patients
Current Research in Translational Medicine, 2016Co-Authors: Perrine Guillaume-jugnot, Aurélie Daumas, Jérémy Magalon, J. Veran, Florence Sabatier, Guy Magalon, Nolwenn Sautereau, B GranelAbstract:Systemic sclerosis is an autoimmune disease characterized by sclerosis (hardening) of the skin and deep viscera associated with microVascular functional and structural alteration, which leads to chronic ischemia. In the hands of patients, ischemic and fibrotic damages lead to both pain and functional impairment. Hand disability creates a large burden in professional and daily activities, with social and psychological consequences. Currently, the proposed therapeutic options for hands rely mainly on hygienic measures, vasodilatator drugs and physiotherapy, but have many constraints and limited effects. Developing an innovative therapeutic approach is crucial to reduce symptoms and improve the quality of life. The discovery of adult stem cells from adipose tissue has increased the interest to use adipose tissue in plastic and regenerative surgery. Prepared as freshly isolated cells for immediate autologous transplantation, adipose tissue-derived stem cell therapy has emerged as a therapeutic alternative for the regeneration and repair of damaged tissues. We aim to update literature in the interest of autologous fat graft or adipose derived from Stromal Vascular Fraction cell-based therapy for the hands of patients who suffer from systemic sclerosis.
B Granel - One of the best experts on this subject based on the ideXlab platform.
-
response to adipose Stromal Vascular Fraction and regenerative therapy in ssc response to the article by magalon et al by de benedetto et al
Annals of the Rheumatic Diseases, 2020Co-Authors: Jérémy Magalon, Francoise Dignatgeorge, Melanie Velier, Stephanie Simoncini, B Granel, Pascale Paul, Florence SabatierAbstract:We would like to thank Di Benedetto et al 1 for their constructive comments on our recent publication in Annals of Rheumatic Disease entitled ‘Molecular profile and proangiogenic activity of the adipose-derived Stromal Vascular Fraction used as an autologous innovative medicinal product in patients with systemic sclerosis’.2 Di Benedetto et al mentioned that the profibrotic signature of mesenchymal stem cells (MSCs) derived from patients with the diffuse cutaneous form of systemic sclerosis (dc-SSc) has been established from previous works. In line with this, they discussed the potential risk of increasing the fibrotic burden by using autologous adipose-derived Stromal Vascular Fraction (ADVSF) in which MSCs are highly represented. Although this is a fair question in the context of developing MSCs-based therapy for SSc, we would like to emphasise the fact that the biological findings …
-
State of the art. Autologous fat graft and adipose tissue-derived Stromal Vascular Fraction injection for hand therapy in systemic sclerosis patients
Current Research in Translational Medicine, 2016Co-Authors: Perrine Guillaume-jugnot, Aurélie Daumas, Jérémy Magalon, J. Veran, Florence Sabatier, Guy Magalon, Nolwenn Sautereau, B GranelAbstract:Systemic sclerosis is an autoimmune disease characterized by sclerosis (hardening) of the skin and deep viscera associated with microVascular functional and structural alteration, which leads to chronic ischemia. In the hands of patients, ischemic and fibrotic damages lead to both pain and functional impairment. Hand disability creates a large burden in professional and daily activities, with social and psychological consequences. Currently, the proposed therapeutic options for hands rely mainly on hygienic measures, vasodilatator drugs and physiotherapy, but have many constraints and limited effects. Developing an innovative therapeutic approach is crucial to reduce symptoms and improve the quality of life. The discovery of adult stem cells from adipose tissue has increased the interest to use adipose tissue in plastic and regenerative surgery. Prepared as freshly isolated cells for immediate autologous transplantation, adipose tissue-derived stem cell therapy has emerged as a therapeutic alternative for the regeneration and repair of damaged tissues. We aim to update literature in the interest of autologous fat graft or adipose derived from Stromal Vascular Fraction cell-based therapy for the hands of patients who suffer from systemic sclerosis.
Aurélie Daumas - One of the best experts on this subject based on the ideXlab platform.
-
Long-term follow-up after autologous adipose-derived Stromal Vascular Fraction injection into fingers in systemic sclerosis patients
Current Research in Translational Medicine, 2017Co-Authors: Aurélie Daumas, Jérémy Magalon, E. Jouve, R. Truillet, D. Casanova, J. Veran, Audrey Benyamine, Françoise Dignat-george, Luca Giraudo, G. MagalonAbstract:Introduction: Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived Stromal Vascular Fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I open-label clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived Stromal Vascular Fraction. Six and 12-month data have been reported. As patients were followed in our medical centre, we report their longer-term outcome beyond the end of the trial. Patients and method: Twelve females, mean age 54.5 ± 10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30 months after treatment. Results: Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted. Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion. Conclusion: Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived Stromal Vascular Fraction injection. Two randomized double blind, placebo-controlled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients.
-
Autologous adipose-derived Stromal Vascular Fraction in patients with systemic sclerosis: 12-month follow-up
Rheumatology, 2016Co-Authors: Perrine Guillaume-jugnot, Aurélie Daumas, Jérémy Magalon, R. Truillet, D. Casanova, Laurent Giraudo, Elisabeth Jouve, Pierre Sebastien Nguyen, Stephanie Mallet, J. VeranAbstract:Objective. Impaired hand function greatly contributes to disability and reduced quality of life in SSc patients. Autologous adipose-derived Stromal Vascular Fraction (ADSVF) is recognized as an easily accessible source of regenerative cells. We reported positive 6-month safety and efficacy results from an open-label clinical trial assessing s.c. injection of autologous ADSVF into the fingers in SSc patients. The objective of this report is to describe the effects at 12 months. Methods. Twelve females, mean age 54.5 years (S.D. 10.3), were assessed 1 year after ADSVF injection. Patients were eligible if they had a Cochin Hand Function Scale score >20/90. ADSVF was obtained from lipoaspirate using an automated processing system and subsequently injected into the s.c. tissue of each finger in contact with neuroVascular pedicles in a one-time procedure. Endpoints were changes in hand disability and skin fibrosis, Vascular manifestations, pain and quality of life at the 12 month follow-up. During the visit, patients estimated the benefit of the procedure with a specific self-completed questionnaire. Results. A significant decrease from baseline of 51.3% (P< 0.001) for Cochin Hand Function Scale score, 63.2% (P< 0.001) for RP severity and 46.8% (P = 0.001) for quality of life (Scleroderma Health Assessment Questionnaire) was observed. A significant improvement of finger oedema, skin sclerosis, motion and strength of the hands and of the Vascular suppression score was also noted. The reduction in hand pain approached statistical significance (P = 0.052). The questionnaire revealed a benefit in daily activities, housework and social activities. Conclusion. ADSVF injection is a promising therapy and appears to have benefits that extend for at least 1 year.
-
State of the art. Autologous fat graft and adipose tissue-derived Stromal Vascular Fraction injection for hand therapy in systemic sclerosis patients
Current Research in Translational Medicine, 2016Co-Authors: Perrine Guillaume-jugnot, Aurélie Daumas, Jérémy Magalon, J. Veran, Florence Sabatier, Guy Magalon, Nolwenn Sautereau, B GranelAbstract:Systemic sclerosis is an autoimmune disease characterized by sclerosis (hardening) of the skin and deep viscera associated with microVascular functional and structural alteration, which leads to chronic ischemia. In the hands of patients, ischemic and fibrotic damages lead to both pain and functional impairment. Hand disability creates a large burden in professional and daily activities, with social and psychological consequences. Currently, the proposed therapeutic options for hands rely mainly on hygienic measures, vasodilatator drugs and physiotherapy, but have many constraints and limited effects. Developing an innovative therapeutic approach is crucial to reduce symptoms and improve the quality of life. The discovery of adult stem cells from adipose tissue has increased the interest to use adipose tissue in plastic and regenerative surgery. Prepared as freshly isolated cells for immediate autologous transplantation, adipose tissue-derived stem cell therapy has emerged as a therapeutic alternative for the regeneration and repair of damaged tissues. We aim to update literature in the interest of autologous fat graft or adipose derived from Stromal Vascular Fraction cell-based therapy for the hands of patients who suffer from systemic sclerosis.
